| Trial Name | Description |
| Checkmate 649 Gastric-GEJ |
Dr. M. Vincent A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic gastric or Gastroesophageal Junction Cancer |
| CO.27 |
Dr. Mark Vincent A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting. |
| CO.21 |
Dr. M. Sanatani A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) |
| RTOG 1112 GI |
Dr. M. Lock Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma |
| CRC.7 GI |
Dr. S. Welch A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total |
| AZ Himalaya GI |
Dr. S. Welch A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma |
| EPOCH GI |
Dr. S. Welch A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy |
This information is updated by the Clinical Research Unit
